富瑞:港交所(0388.HK)季績符預期 予持有評級
富瑞發表研究報吿指,港交所(0388.HK)第三季業績表現符合市場預期,季度淨利潤按季增長17%,按年減少3%,而由於營業額回升,收入按年增長10%,按季增長12%,新股市場亦表現強勁,但受到投資收益減少所抵銷,亦重申主板日均成交具有下行風險,北向交易或受到內地監管可能收緊的影響,該行將港交所目標價由458.52港元輕微調升至459.67港元,予“持有”評級。
該行重申,如果全球不進一步放鬆或增持中國股票,港交所難以於2022年及2023年的成交額達約1900億及約2300億港元。
該行指出,從長遠來看,新產品可以幫助衍生品市場,預期港交所早前推出的MSCI A50期貨合約將在2023年貢獻約4%的收入。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.